The above webinar reviews the inclusion of sex chromosome aneuploidies (SCAs or X and Y chromosome variations) to the California Prenatal Screening Program cfDNA panel, including operational changes for ordering cfDNA screening, key transition logistics, revised result mailers and authorized follow-up services for screen positive cases. Patient counseling considerations and resources for patient education are also presented.

If you would like CME credits for viewing this enduring content, p​​lease complete this evaluation. Upon completion of the evaluation, you will be sent a CME certificate via email in a few weeks.

The Genetic Disease Screening Program has designated this enduring content activity for a maximum of 1.5 AMA PRA Category 1 Credits™​. Physicians should claim only the credit commensurate with the extent of their participation in this activity. The Genetic Disease Screening Program, California Department of Public Health is accredited by the California Medical Association to provide continuing medical education for physicians. None of the speakers, planners or staff involved with this activity have financial relationships with ineligible companies or commercial interests. This activity has not received commercial support.​​

The California Prenatal Screening Program Town Hall: Adding to the Prenatal Screening Panel (webinar recorded November 7, 2023)

Discussing Genetic Conditions and Screen-Positive Results​​ (webinar recorded August 3, 2023)

A special panel of speakers presented on the importance of sensitive delivery of prenatal screening and diagnosis results, the long-term impact of the diagnosis moment, implicit and explicit bias, as well as key recommended practices and resources. 

Speakers included:​